Immune checkpoint inhibitors (ICIs), including monoclonal antibodies that target the programmed cell death protein (ligand) 1 [PD-(L)1] and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), have revolutionized treatments across multiple cancer types [1–3]. The gene discussed is CTLA4; the disease is cancer.